ARS Pharmaceuticals (SPRY)

Anaphylaxis can progress quickly and requires prompt administration of epinephrine. Historically, patients and caregivers have relied on auto-injectors or other injectable formats, which can create hesitation because of needle anxiety, handling concerns, or uncertainty in stressful situations. ARS Pharmaceuticals seeks to address that barrier with a nasal spray format that is portable, simple to administer, and intended for emergency use outside medical settings.

Neffy combines epinephrine with Intravail, a proprietary absorption enhancer that supports uptake through the nasal mucosa. The formulation is designed to deliver epinephrine exposure within the range of approved injectable products while using a low dose and avoiding a needle. This approach aims to preserve the core therapeutic role of epinephrine while improving usability for patients, parents, schools, caregivers, and other people who may need to respond rapidly to a severe allergic reaction.

The company’s business is closely linked to the commercial adoption, regulatory positioning, and market access of neffy across major allergy treatment markets. Its distinctive proposition is the shift from injection-based emergency epinephrine to an intranasal alternative in a category where speed, confidence, and ease of use are central to patient outcomes.